Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a

Tianqi Zhang1, Qiao Zhang1, Xinwei He2

  • 1Department of Population Health, New York University Grossman School of Medicine, New York, NY 10016, USA.

Insights

Combining radiotherapy with immunotherapy shows promise for improving glioma survival. A new four-gene signature may predict treatment response and guide future combination therapies for patients.

Area of Science:

  • Oncology
  • Immunotherapy
  • Radiotherapy

Background:

  • Glioma, including low-grade glioma (LGG), has a high mortality rate.
  • Radiotherapy (RT) combined with immunotherapy (CSF-1R inhibition) has shown potential in preclinical models.
  • Translating these findings to human glioma patients is crucial for improving survival.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying the combination of RT and immunotherapy in glioma.
  • To identify biomarkers for RT resistance and response to combination therapy.
  • To translate findings from mouse models to human glioma patients.

Main Methods:

  • RNA-sequencing data from a mouse glioma model were analyzed.
  • Differentially expressed genes (DEGs) were identified and mapped to the human genome.
  • KEGG enrichment analysis identified significant signaling pathways (PI3K/AKT, Hippo, Notch).
  • Cox regression models selected candidate genes from these pathways.
  • Gene signatures were trained and validated using TCGA and CGGA LGG patient cohorts.

Main Results:

  • A four-DEG signature (ITGB8, COL9A3, TGFB2, JAG1) was identified.
  • This signature demonstrated strong prognostic value, with an AUC of 0.86 for 5-year survival in the validation set.
  • The identified genes are potential intervention targets for combination therapies.

Conclusions:

  • The four-DEG signature has significant prognostic value for RT-treated LGG patients.
  • These DEGs represent potential targets for developing novel combination therapies.
  • Findings support future clinical trial designs for glioma treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K